Particulate ligands, including cholesterol crystals and amyloid fibrils, induce production of interleukin 1b (IL-1b) dependent on the cytoplasmic sensor NLRP3 in atherosclerosis, Alzheimer's disease and diabetes. Soluble endogenous ligands, including oxidized low-density lipoprotein (LDL), amyloid-b and amylin peptides, accumulate in such diseases. Here we identify an endocytic pathway mediated by the pattern-recognition receptor CD36 that coordinated the intracellular conversion of those soluble ligands into crystals or fibrils, which resulted in lysosomal disruption and activation of the NLRP3 inflammasome. Consequently, macrophages that lacked CD36 failed to elicit IL-1b production in response to those ligands, and targeting CD36 in atherosclerotic mice resulted in lower serum concentrations of IL-1b and accumulation of cholesterol crystals in plaques. Collectively, our findings highlight the importance of CD36 in the accrual and nucleation of NLRP3 ligands from within the macrophage and position CD36 as a central regulator of inflammasome activation in sterile inflammation. 
A r t i c l e s
Interleukin 1β (IL-1β) has been linked to the pathogenesis of several sterile inflammatory diseases, including atherosclerosis, Alzheimer's disease and type 2 diabetes. In each of those conditions, the accumulation of particulate materials at sites of inflammation (cholesterol crystals in subendothelial spaces of atherosclerotic plaques 1 , fibrillar amyloid-β in senile plaques in Alzheimer's disease 2 or amyloidcontaining amylin-islet amyloid polypeptide (IAPP) on pancreatic beta cells in type 2 diabetes 3 ) is a hallmark of disease. Studies have identified such particulate endogenous ligands as activators of inflammasomes formed by the cytoplasmic sensor NLRP3 (refs. 4-7) . The NLRP3 inflammasome complex regulates activation of caspase-1, which catalyzes the cleavage of the precursor cytokines pro-IL-1β and pro-IL-18 into their mature, active forms 8 and promotes the secretion of the now biologically active cytokines, as well as of IL-1α 9 . However, the mechanisms by which such structurally distinct molecules activate the NLRP3 inflammasome remain elusive.
Full activation of the NLRP3 inflammasome in macrophages requires the following two steps: priming (signal 1) and activation of inflammasome complex assembly (signal 2). Priming of macrophages increases expression of both pro-IL-1β and NLRP3 (refs. 10-12) and can be achieved in vitro through ligation of the Toll-like receptors (TLRs). Thus, experimental studies typically use bacterial products to prime the NLRP3 inflammasome, as the nature of the immunostimulatory priming signals in atherosclerosis, Alzheimer's disease and type 2 diabetes are not well described. Signal 2 seems to be triggered by perturbation of cytoplasmic homeostasis due to 'lysosomal destabilization' 13 . This process, triggered by certain aggregated and insoluble materials, is characterized by the cytosolic release of lysosomal contents 13 (such as cathepsins) and/or reactive oxygen species 14 , which results in assembly of the NLRP3 inflammasome and activation of caspase-1. Whether signal 1 and signal 2 are unrelated in vivo or whether common molecular events underlie these apparently distinct processes remains undefined.
The mechanisms that control the generation of NLRP3 activators in atherosclerosis, Alzheimer's disease and type 2 diabetes are not well understood. For example, the deposition of cholesterol-rich lipoproteins in the vessel wall is a key pathogenic step in atherosclerosis 15 , yet the origin of cholesterol crystals that accumulate in plaques 1 is poorly understood. Studies of combined confocal-reflection microscopy have shown that crystals are present in early plaques, both in extracellular spaces and in macrophages 4, 16 . In the brain of patients with Alzheimer's disease and the pancreas of patients with diabetes, A r t i c l e s amyloid plaques arise from the aggregation of prefibrillar amyloidogenic peptides such as the amyloid-β peptide of amino acids 1-42 (refs. 17-19) or IAPP [20] [21] [22] , which oligomerize and give rise to higher order structures, including fibrils. Extracellular deposits of IAPPamyloid in the pancreas of patients with type 2 diabetes are associated with the loss of insulin-producing beta cells, and amyloid is also detected in pancreatic macrophages that secrete IL-1β 23, 24 . Similarly, peptides of fibrillar amyloid-β accumulate in extracellular plaques in the brain of patients with Alzheimer's disease, and increasing evidence indicates that soluble forms of amyloid-β are also damaging 25, 26 . The present paradigm suggests that the immunostimulatory aggregates of such NLRP3 agonists form in the extracellular space and that their engulfment by macrophages triggers a process of dysfunctional phagocytosis or lysosomal damage that activates the NLRP3 inflammasome and the release of cytokines of the IL-1 family.
CD36 is an archetypal pattern-recognition receptor that binds polyanionic ligands of both pathogen and self origin 27 and has been linked to the pathogenesis of atherosclerosis and Alzheimer's disease through its recognition of modified endogenous ligands, including oxidized low-density lipoprotein (oxLDL) 28 , fibrillar amyloid-β 29 and soluble amyloid-β 30 . CD36 acts together with a TLR heterodimer of TLR4-TLR6 to recognize oxLDL and fibrillar amyloid-β and to induce the inflammatory response to these endogenous ligands 31 . Mice that lack CD36 (Cd36 −/− mice) are protected from the toxic effects of fibrillar amyloid-β 32 , atherosclerosis 33, 34 , insulin resistance and obesity [35] [36] [37] . Such observations prompted us to investigate the role of CD36 in the priming and activation of the inflammasome in atherosclerosis, Alzheimer's disease and type 2 diabetes. We found that in response to oxLDL, CD36 initiated both signal 1 and signal 2 for complete activation of the NLRP3 inflammasome: CD36 acted together with TLR4-TLR6 to prime the NLRP3 inflammasome, and unabated uptake of oxLDL by CD36, a characteristic of scavenger receptors, resulted in the formation of intracellular cholesterol crystals that caused lysosomal destabilization and NLRP3 activation. We extended that example of NLRP3 activation by particulate ligands formed from within the cell by showing that CD36 also regulated uptake of prefibrillar soluble amyloid-β and of IAPP that were transformed in the lysosome to thioflavin-reactive amyloid that triggered NLRP3. Collectively, our results suggest a new model of lysosome-mediated activation of NLRP3 that occurs from within after new aggregation and transformation of soluble ligands into their pathogenic form. Furthermore, our studies identify ligation of CD36 as the common molecular event that links the recognition of sterile ligands with priming and activation of the NLRP3 inflammasome in atherosclerosis, Alzheimer's disease and type 2 diabetes.
RESULTS

Uptake of oxLDL by CD36 generates NLRP3-activating crystals
Oxidized LDL is a key inflammatory component of atherosclerotic plaques that contains oxidation-specific epitopes that share molecular identity with phosphorylcholine moieties present on Streptococcus pneumoniae 38 . Recognition of that danger-associated molecular pattern by CD36 leads to uptake of oxLDL by recruited monocytes and the formation of cholesterol-laden macrophage foams cells that establish (Fig. 1a, left) . CD36 deficiency did not affect the induction of IL-1β by other activators of NLRP3, including cholesterol crystals generated in vitro or ATP or the synthetic double-stranded DNA poly(dA:dT), which activates the AIM2 inflammasome (Fig. 1a,  right) . To understand how CD36-mediated uptake of oxLDL activated the NLRP3 inflammasome, we used combined confocalreflection microscopy to monitor crystalline material in macrophages.
We observed a dose-and time-dependent increase in the appearance of crystals in macrophages treated with oxLDL but not in those treated with native LDL (Fig. 1b and Supplementary Fig. 1 ), and this was much lower in Cd36 −/− macrophages treated similarly ( Fig. 1b and Supplementary Fig. 1a ). Acetylated LDL and minimally oxidized LDL, which bind SR-A and CD14 (but not CD36), also induced intracellular formation of crystals, albeit to a lesser extent than did oxLDL (Supplementary Fig. 1b) . Treatment with methyl-β-cyclodextrin, to deplete cells of cholesterol, reversed the appearance of reflective material in oxLDL-treated macrophages (Fig. 1c) , which confirmed that this crystalline material was cholesterol. Although CD36 can act as a coreceptor with TLR4-TLR6, oxLDL-induced crystal formation was unimpeded in TLR4-deficient (Tlr4 −/− ) or TLR6-deficient (Tlr6 −/− ) macrophages, and oxLDL-induced secretion of IL-1β from LPS-primed Tlr6 −/− macrophages was similar to that of their wild-type counterparts ( Supplementary Fig. 2a,b) . However, blocking CD36-mediated endocytosis of oxLDL with cytochalasin D inhibited both the formation of intracellular crystals and secretion of IL-1β by LPS-primed macrophages (Fig. 1d,e) , whereas the induction of IL-1β secretion by ATP was unaffected (Fig. 1e) . Notably, despite the similar accumulation of crystals in oxLDL-treated wild-type and NLRP3-deficient (Nlrp3 −/− ) macrophages (Fig. 1f) , secretion of IL-1β was abrogated in Nlrp3 −/− macrophages ( Fig. 1g) , which confirmed the dependence of this response on the NLRP3 inflammasome. Nlrp3 −/− macrophages treated with other activators of NLRP3, including synthetic cholesterol crystals or ATP, also had less secretion of IL-1β (Fig. 1g) . Finally, oxLDL-induced secretion of IL-1β was dependent on caspase-1, as this response was lower in LPS-primed macrophages treated with either a broad caspase-1 inhibitor peptide (ZVAD-fmk) or a specific caspase-1 inhibitor peptide (YVAD-fmk) than in control cells treated with vehicle (Fig. 1h) . This also inhibited IL-1β secretion induced by synthetic cholesterol crystals, ATP and AIM2 (Fig. 1h) . These data established CD36-regulated formation of cholesterol crystals as a key driver of inflammasome activation upstream of NLRP3.
Lysosomes control crystal formation and NLRP3 activation Unlike the receptor for LDL, CD36 is not downregulated by its ligands, which leads to unabated uptake of oxLDL and its cholesterol cargo 39 .
To examine the subcellular localization and fate of oxLDL-induced crystals, we used lysosomal tracers combined with confocal-reflection fluorescence microscopy. After treatment of wild-type macrophages with oxLDL, crystals appeared within 8 h in acidic lysosomal compartments that stained with the lysomotropic dye LysoTracker (Fig. 2a) npg dextran into the cytosol (Fig. 2b) . Cd36 −/− macrophages treated similarly had a punctate perinuclear staining pattern characteristic of intact lysosomes ( Fig. 2a,b) , consistent with oxLDL-induced crystals' being the source of the lysosomal damage. In contrast, treatment with preformed cholesterol crystals induced the release of lysosomal dextran to a similar extent in wild-type and Cd36 −/− macrophages (Fig. 2b) . Unmodified LDL did not disrupt macrophage lysosomal integrity (Fig. 2b) . We confirmed those findings with a fluorescent LysoTracker flow cytometry-based assay in which we quantified lysosomal destabilization by the increase in LysoTracker-negative cells. Consistent with the findings obtained by fluorescence microscopy, treatment with synthetic crystalline cholesterol resulted in a greater frequency of LysoTracker-negative cells among both wild-type macrophages and Cd36 −/− macrophages, but treatment with unmodified LDL did not (Fig. 2c) . In contrast, treatment with oxLDL resulted in more LysoTracker-negative cells among wild-type macrophages but not among Cd36 −/− macrophages (Fig. 2c) . To further investigate the role of lysosomal function in oxLDL-triggered activation of NLRP3, we inhibited lysosomal maturation in macrophages with bafilomycin A1 and observed less IL-1β secretion by macrophages treated with oxLDL or synthetic crystalline cholesterol but not by those treated with ATP or poly(dA:dT) (Fig. 2d) . We similarly observed inhibition of IL-1β secretion in macrophages treated with FA-fmK, a broad inhibitor of the serine-protease family of cathepsins ( Supplementary  Fig. 2c ), which indicated involvement of the release of those lysosomal enzymes in the activation of NLRP3 by oxLDL. Bafilomycin A1 also blocked the formation of cholesterol crystals by oxLDL ( Fig. 2e) , which linked lysosomal activity not just to transmission of the signal to NLRP3 but also to regulating lysosomal cholesterol crystallization. Lysosomal acidification is a key step that is blocked by bafilomycin A1 and is required for the hydrolysis of cholesterol esters in oxLDL by lysosomal acid lipase to free cholesterol, which is more readily crystallized. To determine whether that catabolic event was required for cholesterol crystallization and NLRP3 activation, we treated macrophages with Lalistat, a specific inhibitor of lysosomal acid lipase 40 .
Lalistat abrogated the formation of cholesterol crystals in oxLDLtreated macrophages (Fig. 2f) , as well as the secretion of mature IL-1β (Fig. 2g) , but did not affect IL-1β secretion induced by cholesterol crystals formed in vitro. Together these data supported the proposal of a model of NLRP3 activation distinct from that of 'frustrated phagocytosis' of extracellular particulate materials, in which the unabated uptake of oxLDL by CD36 caused the nucleation and accrual NLRP3-activating crystals in the macrophage.
CD36 and TLR4-TLR6 together prime the inflammasome
The dual requirement for priming and activating signals for full activation of NLRP3 acts as a safeguard against the accidental or uncontrolled release of IL-1β. During the course of our studies, we noted that oxLDL had the unusual ability to induce the secretion of mature IL-1β from unprimed macrophages, a response dependent on CD36 (Fig. 3a) . As signal 1 often proceeds through TLRs, we investigated whether cooperative signaling via CD36 with TLR4-TLR6 provided the oxLDL priming signal. Treatment of macrophages with oxLDL alone induced modest secretion of IL-1β that was not enhanced in the presence of the NLRP3 activator ATP (Fig. 3a) ; this confirmed that oxLDL was able to provide both signal 1 and signal 2 for NLRP3 activation. Notably, IL-1β production was impaired in Cd36 −/− , Tlr4 −/− or Tlr6 −/− macrophages (Fig. 3a) , which indicated that the heterotrimeric (CD36-TLR4-TLR6) signaling complex was required for the priming of NLRP3 by oxLDL. We obtained similar results when we primed macrophages with oxLDL but used cholesterol crystals as the NLRP3 activator (Supplementary Fig. 2d ). Because we detected such modest amounts of IL-1β when oxLDL was the priming agent, we assessed the oligomerization of ASC (a component 
npg
A r t i c l e s of the NLRP3 inflammasome) labeled with cyan fluorescent protein (ASC-CFP) to further investigate the role of oxLDL in NLRP3 priming 11 . ASC-CFP was polydispersed throughout the cytoplasm in unstimulated macrophages; however, supramolecular assembly of ASC occurred after signal 1 and signal 2, as noted in cells primed with LPS and subsequently treated with ATP (Fig. 3b, bottom left) . Treatment with oxLDL alone induced the formation of ASC complexes (Fig. 3b) , consistent with the idea that oxLDL not only primed but also activated NLRP3. Treatment with ATP after priming with oxLDL also induced the formation of speck-like complexes, albeit at a lower frequency than that in LPS-primed cells (Fig. 3b,c) .
CD36 primes the NLRP3 inflammasome in vivo
To explore the role of CD36-TLR4-TLR6 in transducing the priming signal of oxLDL, we assessed the requirement for this signaling complex in the transcriptional induction of inflammasome substrates and NLRP3 itself. OxLDL induced the expression of Il1b and Il1a mRNA in wild-type macrophages, but LDL did not, whereas expression of Il18 mRNA was unchanged, consistent with its high basal expression in macrophages ( Fig. 3d and Supplementary Fig. 3) . Furthermore, oxLDL also induced expression of Nlrp3 mRNA, a critical checkpoint in NLRP3 priming, but not of Nlrc4, which encodes a Nod-like receptor (NLR) involved in recognition of bacteria (Fig. 3d) . Notably, we did not observe induction of the expression of Il1a, Il1b or Nlrp3 mRNA in Cd36 −/− , Tlr4 −/− or Tlr6 −/− macrophages treated with oxLDL (Fig. 3d) .
Triggering of CD36-TLR4-TLR6 by oxLDL induces activation of the transcription factor NF-κB and reactive oxygen species 31 , two signals required for effective priming of the NLRP3 inflammasome. Consistent with that, the induction of expression of Il1a, Il1b and Nlrp3 mRNA by oxLDL was inhibited by BAY 11-7082, an inhibitor of the inhibitor of NF-κB kinase IKKβ (Fig. 3e) , and by diphenylene iodonium, an inhibitor of the NADPH oxidase enzyme complex (Fig. 3f) . These data indicated that CD36-TLR4-TLR6, acting via NF-κB and reactive oxygen species, primed the NLRP3 inflammasome in response to oxLDL.
The endogenous NLRP3-priming signals in atherosclerosis remain unclear. We postulated that recognition by CD36 of oxidized forms of LDL that accumulate during hypercholesterolemia can prime macrophages in vivo. To test this, we used an in vivo model of foam-cell formation by isolating peritoneal macrophages from atherosclerosissusceptible mice deficient in apolipoprotein E (Apoe −/− mice) and Cd36 −/− Apoe −/− mice fed an atherogenic, high-fat, high-cholesterol Western diet for 12 weeks. Macrophages isolated from those Apoe −/− mice had a greater abundance of Il1a, Il1b and Nlrp3 mRNA than did macrophages from normolipidemic wild-type mice (Fig. 3g) , which indicated that these cells were primed in vivo for NLRP3 activity. That enhancement of NLRP3-priming signals was specific, as we detected no difference between the cells in their abundance of Il18 mRNA or Nlrc4 mRNA. In contrast, the abundance of Il1a, Il1b and Nlrp3 mRNA in macrophages from Cd36 −/− Apoe −/− mice fed a Western diet was similar to that of macrophages from wild-type mice fed regular chow. Furthermore, for macrophages obtained from Apoe −/− mice fed a Western diet, treatment ex vivo with the NLRP3 activator ATP (signal 2) induced secretion of IL-1β, whereas we detected no enhanced secretion of IL-1β by macrophages from Cd36 −/− Apoe −/− mice treated similarly (Fig. 3h) . Moreover, secretion of IL-1α, a function dependent on the inflammasome, was similarly enhanced in macrophages obtained from Apoe −/− mice fed a Western diet and treated with ATP, but not in their Cd36 −/− Apoe −/− counterparts (Fig. 3i) . These data demonstrated a requirement for CD36 in the priming of NLRP3 in macrophages by atherogenic stimuli in vivo.
Targeting CD36 diminishes inflammasome activation in vivo
To further investigate the role of CD36 and its signaling partners TLR4-TLR6 in priming and activation of the inflammasome in vivo, we generated Apoe −/− mice deficient in CD36, TLR4 or TLR6 and fed them a Western diet for 12 weeks. Despite similar concentrations of total cholesterol in all groups (Supplementary Table 1 less aortic plaque formation than did Apoe −/− control mice ( Fig. 4a and Supplementary Fig. 4) . The doubly deficient mice also had lower serum concentrations IL-1β, IL-1α and IL-18 ( Fig. 4b) , as well as a lower abundance of Il1a, Il1b and Nlrp3 mRNA in the aorta (Fig. 4c) , indicative of diminished inflammasome activity. Furthermore, measurement of the accumulation of cholesterol crystals in plaques by confocal reflection microscopy showed a lower crystal burden specifically in Cd36 −/− Apoe −/− mice (Fig. 4d,e) , which supported the hypothesis that CD36 regulates inflammasome activity during atherogenesis by modifying both signal 1 and signal 2. We also observed less staining of IL-1β and active caspase-1 in plaques of Cd36 −/− Apoe −/− , Tlr4 −/− Apoe −/− and Tlr6 −/− Apoe −/− mice than in those of Apoe −/− control mice (Fig. 4f) . Nevertheless, there was less IL-1β and caspase-1 in Cd36 −/− Apoe −/− plaques than in Tlr4 −/− Apoe −/− or Tlr6 −/− Apoe −/− plaques (Fig. 4f) , consistent with a critical role for CD36 in both priming and activating the NLRP3 inflammasome. We next determined whether therapeutic targeting of CD36 with an antisense oligonucleotide (ASO) that potently inhibited CD36 expression in macrophages in vitro and in vivo ( Supplementary  Fig. 5 ) would prevent inflammasome activation in Apoe −/− mice fed a Western diet. Notably, the serum concentration of IL-1β increased over 4 weeks in Apoe −/− mice that received weekly injections of a control (nontargeting) ASO but not in those given the CD36-specific ASO (Fig. 4g) .
CD36 regulates amyloid formation and NLRP3 activation
Like atherosclerosis, Alzheimer's disease is characterized by a protracted inflammatory response driven by cells of the monocyte lineage. Fibrillar amyloid-β activates the NLRP3 inflammasome and secretion of IL-1β in LPS-primed macrophages and microglia 5 , and activation of NLRP3 has been shown to contribute to Alzheimer's disease 41 . CD36 binds to soluble (prefibrillar) amyloid-β 30 , which prompted us to investigate whether uptake of that soluble ligand by CD36 would also promote the intracellular generation of an NLRP3 activator. We treated macrophages with soluble amyloid-β, which we confirmed was nonfibrillar (Supplementary Fig. 6a) , and stained the cells with thioflavin-S, a dye that becomes fluorescent after it binds amyloid oligomers and fibrils. Confocal microscopy showed a timedependent increase in the appearance of intracellular thioflavin-S fluorescence in wild-type macrophages treated with soluble amyloid-β but not in their Cd36 −/− counterparts (Fig. 5a) . Macrophages incubated with a nonamyloidogenic 'reverse' amyloid-β peptide (with the amyloid-β amino acid sequence in reverse order) showed no evidence of thioflavin-S-reactivity for up to 24 h, whereas thioflavin-S-reactive amyloid was apparent in wild-type macrophages as early as 3 h after the addition of soluble amyloid-β, and it localized to lysosomes (Fig. 5a,b) . We detected no extracellular or cell-associated fibrils by confocal microscopy (Fig. 5a,b) , and soluble amyloid-β incubated for up to 24 h at 37 °C in cell culture medium showed no evidence of reactivity with thioflavin-T (an anaolog of thioflavin-S for in vitro assays; Supplementary Fig. 6b ). Over that time frame (3-24 h), soluble amyloid-β induced the progressive release of IL-1β when incubated with LPS-primed wild-type macrophages but not when incubated with their Nlrp3 −/− or caspase-1-deficient (Casp1 −/− ) counterparts ( Fig. 5c and Supplementary Fig. 6b, bottom) , which indicated that uptake of this soluble ligand resulted in activation of NLRP3. Of note, soluble amyloid-β was as effective an NLRP3 activator as was fibrillar amyloid-β, and pretreating macrophages with Congo red to interfere with the formation of β-sheets blocked the secretion of IL-1β induced by soluble amyloid-β (Fig. 5d) . Finally, the secretion of IL-1β induced by soluble amyloid-β was abrogated in Cd36 −/− macrophages (Fig. 5e) , which indicated a critical role for this receptormediated uptake pathway in the generation of intracellular NLRP3-activating amyloid.
Studies have identified activation of the NLRP3 inflammasome by another amyloidogenic peptide, IAPP, as a mechanism for the enhanced IL-1β in type 2 diabetes 6 . Notably, IAPPs delivered to macrophages in a soluble form are the 'preferential' activators of NLRP3 (ref. 6). We postulated that CD36-mediated uptake of IAPP may promote intracellular amyloid formation and NLRP3 activation, (Fig. 6a) . Furthermore, wild-type macrophages incubated with soluble human IAPP showed a time-dependent increase in intracellular thioflavin-S fluorescence, but their Cd36 −/− counterparts did not (Fig. 6b) . We observed no such increase in thioflavin-S staining in macrophages treated for up to 24 h with rat IAPP, which is nonamyloidogenic because of species-specific differences in amino acids (Fig. 6b) , or when we incubated soluble IAPP at 37 °C in cell culture medium alone (Supplementary Fig. 6c) . The intracellular accumulation of thioflavin-S-reactive amyloid altered lysosomal stability, as wild-type macrophages treated with fluorescent dextran and incubated for 24 h with human IAPP or soluble amyloid-β showed a loss of lysosomal integrity and leakage of dextran into the cytoplasm (Fig. 6c) . Soluble IAPP induced the progressive release of IL-1β, from as early as 3 h, when incubated with LPS-primed wildtype macrophages but not when incubated with their Nlrp3 −/− or Casp1 −/− counterparts ( Fig. 6d and Supplementary Fig. 6c) . Notably, the lysosomal damage induced by those amyloidogenic peptides, and subsequent IL-1β secretion, were abrogated in Cd36 −/− macrophages (Fig. 6c,e) . Furthermore, pretreatment of macrophages with Congo red blocked the accumulation of thioflavin-reactive IAPP and secretion of IL-1β (Fig. 6f) , which indicated that the intracellular transformation of soluble IAPP resulted in activation of NLRP3. Moreover, and consistent with the results we obtained with oxLDL-induced cholesterol crystals, phagolysosomal activity was required for the activation of NLRP3 by human IAPP and soluble amyloid-β, as pretreatment with cytochalasin D to block endocytosis, with bafilomycin A1 to block lysosomal acidification or with FA-fmk to inhibit the serine-protease family of cathepsins blunted IL-1β production ( Supplementary Fig. 6d,e) . These data supported the proposal of a common pathway through which CD36-mediated uptake of the soluble precursors of NLRP3 ligands facilitated the intracellular generation of pathogenic activators of NLRP3.
DISCUSSION
Our work here has identified CD36 as a master regulator of inflammasome activation in atherosclerosis, Alzheimer's disease and type 2 diabetes that facilitated the accrual and intralysosomal conversion of soluble endogenous ligands (oxLDL, soluble amyloid-β and IAPP) into insoluble crystals or amyloid oligomers and fibrils and, consequently, the activation of NLRP3 that led to IL-1β secretion. Lysosomal dysfunction has a critical role in both the generation of crystalline and amyloid ligands and the transmission of the damaging effects of those ligands sensed by NLRP3. Our results npg suggest a new model of NLRP3 activation by particulate ligands formed in the macrophage and place CD36 upstream of a common mechanism of NLRP3-dependent IL-1β secretion in several sterile inflammatory diseases. In each of the diseases focused on in this study, the accumulation of particulate materials at sites of inflammation is a pathological hallmark. Unlike previously proposed models of NLRP3 activation in these diseases in which 'frustrated phagocytosis' of extracellular particulate materials triggers the inflammasome 4,5 , our findings suggested that the earliest activation of NLRP3 by cholesterol crystals or amyloid-β-IAPP fibrils resulted from recognition and endocytosis of the soluble precursors of particulate ligands (such as oxLDL, soluble amyloid-β and soluble IAPP) by CD36 and the subsequent intracellular nucleation of insoluble NLRP3 activators. Our data fit with published observations of intracellular formation of amyloid fibrils in vitro [23] [24] [25] [26] 42, 43 , and an increasing literature that suggests that soluble amyloid-β and soluble IAPP are the damaging species in Alzheimer's disease and type 2 diabetes, respectively. Macrophages incubated with soluble amyloid-β and soluble IAPP may contain higher order oligomeric forms of these peptides, as well as fibrillar forms of amyloid in the lysosome that may activate NLRP3. Although our results do not exclude the possibility that extracellular crystals or amyloid fibrils that accumulate during disease also activate the NLRP3 inflammasome through the 'frustrated phagocytosis' process, here we have expanded on that paradigm by suggesting that such ligands may be secondary triggers of NLRP3 that arise later in disease because of their active export from macrophages or the release of crystals or fibrils from dying cells. Macrophage death may itself be triggered by activation of the inflammasome through the process of pyroptosis 44 , which is linked to the release of proatherogenic IL-1α [45] [46] [47] , or as a result of lysosomal dysfunction due to the prolonged accumulation of insoluble crystals or fibrils.
In atherosclerosis, CD36 has a dual role in initiating both priming (signal 1) and activation (signal 2) of the NLRP3 inflammasome. Although oxLDL has been known to trigger IL-1β production in foam cells [48] [49] [50] , many of those studies were done before the discovery of the NLRP3 inflammasome. Our work has identified the molecular mechanism by which oxLDL induces macrophage secretion of IL-1β by showing that binding of oxLDL by CD36 controlled engagement of the two pathways necessary for full activation of the inflammasome: signal 1 (via the TLRs) and signal 2 (via the NLRs). Although published studies of inflammasome activity in host defense and inflammatory disease have suggested that signal 1 and signal 2 are derived from the engagement of distinct signaling pathways by separate dangerassociated molecular patterns, our data have suggested that a single such pattern (oxLDL) provided both signals in atherosclerosis by engaging CD36. Although the amount of priming signal induced by oxLDL via CD36-TLR4-TLR6 was modest compared with that induced by bacterial stimuli, it was consistent with the idea of atherosclerosis arising from low-grade inflammation over a protracted period of time, and our in vivo data confirmed the importance of this receptor complex in both the priming of NLRP3 and the formation of atherosclerotic plaques. Notably, CD36 deficiency in Apoe −/− mice also resulted in much less accumulation of cholesterol crystals in plaques and serum concentrations of cytokines of the IL-1 family (IL-1β, IL-1α and IL-18), which indicated that the CD36-dependent pathway for intracellular crystal generation identified in vitro was also active in vivo. The endocytosis of ligands by CD36, which led to the nucleation of NLRP3 activators, can therefore be thought of as 'signal 0' in models of inflammasome activation by sterile inflammatory stimuli, which provides the common cellular event required for priming and activation of NLRP3 in metabolic diseases.
The incidence of atherosclerosis and type 2 diabetes continues to increase, and the development of new therapeutics for metabolic disease is crucial. Appreciation of the critical role of the NLRP3 inflammasome in both atherogenesis and type 2 diabetes indicates the promise of this pathway for therapeutic targeting. Although many studies have described regulators of inflammasome activity at the level of complex assembly and caspase-1 activation 51 , the identification of CD36 as a key upstream regulator of NLRP3 activation by endogenous 'danger ligands' in atherosclerosis, Alzheimer's disease and type 2 diabetes provides a new target for therapeutic intervention that does not compromise the inflammasome activity required for host defense against pathogens. To our knowledge, this is the first such upstream regulator of NLRP3 described in sterile inflammation, with CD36 fulfilling a role analogous to that of the receptor P2X7 in ATP-mediated NLRP3 activation 52 . Targeting CD36 for amelioration of NLRP3 activation may be particularly useful for atherosclerosis, in which CD36 is essential for priming and activation of the inflammasome in macrophage foam cells, as well as the accumulation of cholesterol crystals in plaques. In support of that, we found that targeting CD36 with ASOs resulted in lower serum concentrations of IL-1β in atherosclerotic mice, which suggests that such strategies may hold promise for diminishing inflammasome activation in human disease.
METHODS
Methods and any associated references are available in the online version of the paper.
Silencing of CD36 in vitro was assessed by transfection of immortalized macrophages with 10 ng ASO per well in 12-well plates with Lipofectamine RNAiMax (Invitrogen).
Serum array and ELISA. Mouse serum was used for multiplex analysis of cytokines with Quantibody Mouse Inflammation Array 1 (QAM-INF-1) according to the manufacturer's instructions (RayBiotech). The Mouse IL-18 ELISA Kit (7625; MBL) was used for ELISA of IL-18 in serum. Specific DuoSet ELISA kits (DY401 (IL-1β) and DY400 (IL-1α); R&D Systems) were used ELISA of supernatants.
Microscopy. For analysis of speck formation in macrophages transfected to express ASC-CFP, cells were seeded in eight-well Lab-Tek chamber slides (Thermo Scientific) and, after the experiment, were fixed in 4% paraformaldehye (IC Fixation Buffer, 1x concentrate; Invitrogen), washed with PBS and stained with Alexa Fluor 594-coupled cholera toxin subunit B (2 µg/ml; Invitrogen) and counterstained with DAPI (4′,6-diamidino-2-phenylindole; 0.5 µg/ml; Sigma) before being mounted with Fluorescent Mounting Medium (Dako). Cells were visualized by confocal microscopy (Zeiss 600 System). Images obtained at a magnification of ×63 were merged with ImageJ software. For quantification of speck formation, images were obtained by epifluoresence microscopy at a magnification of ×20. For analysis of crystal formation alongside lysosomal markers, live-cell imaging was done. For this, cells were seeded in 35-mm Petri dishes on 0.16-mm coverglasses and were allowed to adhere overnight. Cells were then pretreated for 1 h with Alexa Fluor 647-coupled dextran (10 kDa; 50 µg/ml; Invitrogen) or LysoTracker Red DND-99 (100 nM), followed by treatment with inflammasome activators. Combined confocal reflection microscopy was done at various time points with a Leica SP2 AOBS confocal laser-scanning microscope as described 13 . For analysis of amyloid formation, cells were seeded in eight-well Lab-Tek chamber slides as described above and, after the experiments, were fixed in 10% paraformaldehyde, washed with PBS, stained with Alexa Fluor 594-coupled cholera toxin subunit B as described above, washed with PBS, permeabilized for 20 min with 0.1% Triton X-100 and stained with 0.01% thioflavin-S. After being stained, cells were washed five times with 70% ethanol, followed by two washes with PBS, then were stained with DAPI and mounted as described above. Cells were imaged with a Nikon Ti inverted microscope (Eclipse) with Ultraview Spinning Disc confocal scanner (CSU-X1; PerkinElmer). Images were captured with an Orca-ERCamera with Volocity (PerkinElmer). Volocity software was used for post-acquisition analysis, such as contrast adjustment, deconvolution through iterative restoration and three-dimensional reconstruction.
Immunofluorescence staining. Slides containing eight sections covering the aortic root were fixed in acetone, blocked with 10% serum (specific to the species in which the secondary antibodies were raised) in PBS and were stained overnight at 4 °C with anti-CD68 (rat antibody to mouse immunoglobulin G (IgG); MCA1957; FA-11; Serotec) at a concentration of 2 µg/ml or anti-IL-1β (goat antibody to mouse IgG; AF-401-A; R&D Systems) at a concentration of 1 µg/ml. Slides were washed and then incubated for 2 h at 21 °C with the following secondary antibodies (each at a concentration of 2 µg/ml): Alexa Fluor 568-coupled goat antibody to rat IgG (for CD68 staining) or Alexa Fluor 568-coupled rabbit antibody to goat IgG (for IL-1β staining). Sections were then incubated for 2 h at 21 °C with fluorescent peptide-based probes for active caspase-1 (FAM-YVAD-fmk; FLICA Caspase 1 Kit 98; ImmunoChemistry Technologies), used at a concentration of 3×. Slides were then washed and counterstained with DAPI before mounting as described above. Aortic root plaques were visualized with epifluoresence microscopy. For quantification of caspase-1 activity and staining for IL-1β, the area positive for staining in plaques was calculated as a percentage of total area with ImageJ software. For analysis of plaque crystal content, tissue sections were fixed with 4% paraformaldehyde for the preservation of crystalline material, nuclei were stained with Hoechst 33342 (Immunochemistry) and combined confocal reflection microscopy was done with a Leica TCS SP5 II AOBS confocal laser-scanning microscope as described 13 . Plaque crystal content was quantified with Volocity Quantitation (PerkinElmer) and is presented relative to total plaque area. 
